VivoSeq
Other

Hemodialysis

0

Pipeline Programs

11

Active Trials

18

Companies Involved

Hemodialysis is an early-stage landscape with 0 programs across 18 companies. The most active players are Roche, Sanofi, Pathalys Pharma.

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

85/100

Attrition Rate

11/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

107

clinical trials

Completed70 · 65%
Unknown status14 · 13%
Terminated7 · 7%
Withdrawn5 · 5%
Recruiting5 · 5%
Not yet recruiting3 · 3%
Other3 · 3%

Trial Activity

107 trials

Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation
Recruiting··Phase 2·NCT05498181·100 enrolled
Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL)
Active, not recruiting·UUniversity Hospital, Tours·Phase 4·NCT06093269·32 enrolled
Alpha Lipoic Acid in Pediatrics on Hemodialysis
Enrolling by invitation··Phase 3·NCT06286098·50 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)